GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain. Neuroreport. 2016;27:384–391. doi: 10.1097/WNR.0000000000000548.
GLP-1, Parkinson’s Disease, and Neuroprotection | NEJM
Apr 3, 2024 · Parkinson’s disease is a common and debilitating disorder. The best-known features are resting tremor, rigidity, and slowness, but recently a fuller picture of the associated complications has...
Trial of Lixisenatide in Early Parkinson’s Disease
Apr 3, 2024 · Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease.
GLP‐1 Agonists as Potential Neuromodulators in Development of Parkinson …
1 day ago · Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may act as neuromodulators in neurodegenerative disorders , and a recent phase 2, randomized trial, enrolling 157 patients with early Parkinson's disease, reported that lixisenatide (GLP-1RA) prevented worsening of symptoms over a 1-year period based on the Movement Disorder Society–Unified ...
Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease
Nov 5, 2024 · The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01
GLP‐1 receptor agonists for Parkinson's disease: An updated …
Jan 1, 2025 · GLP-1 receptor agonists may decrease neuroinflammation by reducing microglia activation in Parkinson's Disease. This study evaluates the efficacy of GLP-1 receptor agonists in improving Parkinson's Disease symptoms.
Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a …
Accumulating evidence supports the evaluation of glucagon-like peptide-1 (GLP-1) receptor (R) agonists for the treatment of the underlying pathology causing Parkinson’s Disease (PD).
Exenatide once a week versus placebo as a potential disease …
6 days ago · There are strong epidemiological data supporting a protective effect of GLP-1 receptor agonists against the development of Parkinson's disease among people with type 2 diabetes. 10,11 Given the potential beneficial effects on improved glucose control against the complications of diabetes, such as cerebrovascular disease and peripheral ...
GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease
Mar 29, 2024 · Many data on animal models and preclinical studies show that GLP1-R agonists can restore dopamine levels, inhibit dopaminergic loss, attenuate neuronal degeneration and alleviate motor and non-motor features of PD.
GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson …
Background: Parkinson's disease is a progressive neurodegenerative disorder with no cure. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have neuroprotective effects. However, long-term real-world studies are needed to clarify their potential impact on …